PALO ALTO, Calif.--(BUSINESS WIRE)--Vivo Capital (“Vivo” or the “Firm”), a leading global investment firm focused exclusively on healthcare and life sciences, today announced multiple legal proceedings to challenge the irresponsible actions taken by the current Board of Directors of Sinovac Biotech Ltd. (NASDAQ
VA) (“Sinovac” or the “Company”) under the control of the activist investor 1Globe Capital LLC (“1Globe”) and its allies. In January 2025, the Judicial Committee of the Privy Council in.
